Information Provided By: 
Fly News Breaks for November 5, 2018
IMMU
Nov 5, 2018 | 08:12 EDT
As previously reported, Morgan Stanley analyst Matthew Harrison initiated Immunomedics with an Overweight rating, stating that he expects IMMU-132 to be approved by its PDUFA date in January 2019 and expects rapid adoption of the drug after that. The drug is initially focused in late-line triple negative breast cancer, but he believes expansion to earlier lines of therapy can drive over $1B in peak sales, Harrison tells investors. He set a $38 price target on Immunomedics shares.
News For IMMU From the Last 2 Days
There are no results for your query IMMU
